Patient-Centric Approach To Accelerating Clinical Trials

In an interview with Life Sciences Review, Anita Nelsen, senior vice president, clinical trial operations, Allucent, provides a general outlook on the current clinical trial landscape and highlights the value of a patient-centric approach. Click below to read the full article. Read here

How to Overcome Challenges in Combination Immunotherapy Clinical Trials

Immunotherapy has quickly become a major focus in the world of cancer research and treatment. In recent years, there has been a surge in the number of biotech companies conducting clinical trials for combination immunotherapies.   What are Combination Immunotherapies?  The combination immunotherapy approach involves the use of two or more different types of immunotherapies in […]

Long-Term Follow-Up for CGT Trials: Best Practices to Operationalize

By Desmond Cabrera, Project Director, Cell and Gene Therapy With today’s cutting-edge technology, we are on the cusp of developing truly magnificent therapies using cell and gene science. However, as with any new therapy, we must always consider the patient first.   Guidelines to Ensure Patient Safety  As far back as 2001, as new cell and […]

The Role of Statisticians in Study Design and Why to Engage them Early

By Melanie Buitendyk, Director, Biostatistical Consulting  A Sponsor has a promising therapy and is in the process of planning their clinical development strategy. Key components of this planning include regulatory and corporate objectives, go-no-go decisions, and on a study level, includes study design, study objectives, and endpoints. Well-planned, well-designed, and well-written protocols are essential in […]

Benefits of Bayesian Dose Escalation Designs for Oncology Studies

As acceptance of flexible trial designs continues to advance, many sponsors are increasingly exploring alternate methods for dose escalation to support identification of a maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) in open-label Early Phase or First in Human studies. Bayesian dose escalation designs have also coincided with advances in oncology therapy […]

A Snapshot of Gap Analysis

When building a successful regulatory strategy, it is critical to keep the end objectives in mind and design a process that is tailored to your specific product. Planning for regulatory requirements can help you avoid non-compliant practices from the very beginning, but how do you make sure your strategy is comprehensive? The answer may be […]

The Essential Role of the CMC Expert

Recently, our colleague Marcus Delatte offered his insights about how a nonclinical expert1 can support the product development process and further advise sponsors on their applications for drug and marketing authorization approvals. The role of the Chemistry, Manufacturing, and Controls (CMC) expert is no less important. CMC applies to the entire drug product development lifecycle, beginning […]

Mind the Gap: The Importance of Gap Analysis in Securing Regulatory Approval

Significant pressure to achieve regulatory approval to start generating return on investment can affect any sponsor, but it is of the greatest importance to small biopharma companies without existing marketed products. Biopharma companies may have conducted successful research and put in the work to warrant approval and market access, but to an uninitiated sponsor bridging […]

How to Choose Sites for Cancer Trials: Central and Eastern Europe

Site location can have a significant impact on clinical trial success. Study protocols often have established timelines and budget restrictions that offer little room for flexibility. There are also different regulations and regulatory timelines that have to be considered and managed – and that’s when there isn’t a pandemic. The COVID-19 Crisis has forced many researchers to […]